AMENDMENTS TO THE CLAIMS

- 1. (Currently Amended) A polypeptide isolated from mammals, eomprising consisting of, at its C-terminal end, a heptapeptide having the following sequence: Cys-Phe-Trp-Lys-Tyr-Cys-Xaa, in which Xaa represents Val or Ile, in that it belongs to the urotensin II family and is selected from the group consisting of the human sequences SEQ ID NO:1-3

 SEQ ID NO:1-2, the rat sequences SEQ ID NO:30-32, and the mouse sequences SEQ ID NO:33-35.
 - 2. 8. (Cancelled)
- 9. (Currently Amended) A pharmaceutical composition, comprising at least one polypeptide isolated form from mammals eomprising consisting of, at its C-terminal end, a heptapeptide having the following sequence: Cys-Phe-Trp-Lys-Tyr-Cys-Xaa, in which Xaa represents Val or Ile, in that it belongs to the urotensin II family and is selected from the group consisting of the human sequences SEQ ID NO:1-3 SEQ ID NO:1-2, the rat sequences SEQ ID NO:30-32, and the mouse_sequences SEQ ID NO:33-35 combined with at least one pharmaceutically acceptable vehicle.
- 10. (Previously Presented) A method of making a medicinal product comprising admixing at least one polypeptide according to claim 1 with at least one pharmaceutically acceptable vehicle.
 - 11. 13. (Cancelled)
- 14. (Currently Amended) A method for selecting candidate anti-hypertensives comprising determining the activity of an <u>said candidate</u> anti-hypertensive against a urotensin II family member selected from the group consisting of the human sequences SEQ ID NO:1-3 <u>SEQ ID NO:1-2</u>, the rat sequences SEQ ID NO:30-32, and the mouse sequences SEQ ID NO:33-35 as an antagonist.

Serial No.: 09/831,907

Further to the Advisory Action mailed January 26, 2004 and in Reply to Office Action of October 1, 2003

15. (Currently Amended) The polypeptide claimed in claim 1 wherein said polypeptide is selected from the group consisting of the human sequences SEQ ID NO:1-3 SEQ ID NO:1-2.

- 16. (Previously Presented) The polypeptide claimed in claim 1 wherein said polypeptide is selected from the group consisting of the rat sequences SEQ ID NO:30-32.
- 17. (Previously Presented) The polypeptide claimed in claim 1 wherein said polypeptide is selected from the group consisting of the mouse sequences SEQ ID NO:33-35.
- 18. (New) The pharmaceutical composition claimed in claim 9 wherein said polypeptide is selected from the group consisting of the human sequences SEQ ID NO:1-2.
- 19. (New) The pharmaceutical composition claimed in claim 9 wherein said polypeptide is selected from the group consisting of the rat sequences SEQ ID NO:30-32.
- 20. (New) The pharmaceutical composition claimed in claim 9 wherein said polypeptide is selected from the group consisting of the mouse sequences SEQ ID NO:33-35.
- 21. (New) The method claimed in claim 10 wherein said polypeptide is selected from the group consisting of the human sequences SEQ ID NO:1-2.
- 22. (New) The method claimed in claim 9 wherein said polypeptide is selected from the group consisting of the rat sequences SEQ ID NO:30-32.
- 23. (New) The method claimed in claim 9 wherein said polypeptide is selected from the group consisting of the mouse sequences SEQ ID NO:33-35.
- 24. (New) The method claimed in claim 14 wherein said polypeptide is selected from the group consisting of the human sequences SEQ ID NO:1-2.
- 25. (New) The method claimed in claim 14 wherein said polypeptide is selected from the group consisting of the rat sequences SEQ ID NO:30-32.
 - 26. (New) The method claimed in claim 14 wherein said polypeptide is selected from

Serial No.: 09/831,907

Further to the Advisory Action mailed January 26, 2004 and in Reply to Office Action of October 1, 2003

the group consisting of the mouse sequences SEQ ID NO:33-35.

Serial No.: 09/831,907

Further to the Advisory Action mailed January 26, 2004 and in Reply to Office Action of October 1, 2003

SUPPORT FOR THE AMENDMENTS

Claim 2-8 and 11-13 have been cancelled.

Claims 1, 9, 14, and 15 have been amended.

The amendment of Claims 1, 9, 14, and 15 are supported by the claims as originally filed, most notably Claim 2, as well as the corresponding claims as previously presented.

No new matter has been added by the present amendment.